Tissium Receives Investigational Device Exemption for Vascular Sealant

November 20, 2020

The FDA has approved Tissium’s investigational device exemption request for a vascular sealant it is developing.

The sealant, which is designed to quickly achieve hemostasis and prevent post-operative bleeding after peripheral vascular surgeries, is now cleared for a U.S. clinical trial.

Tissium CEO Christophe Bancel said the approval represents "a key milestone” for the investigational device but did not say when the company plans to start its trial.

View today's stories